Pfizer's (NYSE: PFE) share price has fallen more than the S&P 500 so far this year. If you're a growth investor, you probably won't be interested in buying Pfizer stock. Pfizer's top-selling product ...

Zacks Investment Research Image Source: Zacks Investment Research Presently, Pfizer looks like a discounted stock ... Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev ...

Image Source: Zacks Investment Research Presently, Pfizer looks like a discounted stock as well ... Pfizer's growth is boosted by Nurtec ODT, acquired from Biohaven and Padcev from the Seagen ...

By most standards, Pfizer looks like the proverbial knife in the investing ... such as cancer therapies Adcetris and Padcev along with migraine drug Nurtec ODT, that should help offset the revenue ...

Income investors should especially like Pfizer because ... with migraine drug Nurtec ODT, that should help offset the revenue declines. In addition, Pfizer's pipeline looks promising with 115 ...

So it looks like the Seagen acquisition - while being costly for the firm initially - will likely be paid back eventually in terms of the firm's enhanced market positioning and greater revenue and ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... Such an approach will likely increase the overall quality of the portfolio and metrics like Return on Equity and revenue ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE ... increase the overall quality of the portfolio and metrics like Return on Equity and revenue growth rate, which are ...